Experimental Duchenne Muscular Dystrophy Treatment Earns Rare Pediatric Disease Designation
source: pixabay.com

Experimental Duchenne Muscular Dystrophy Treatment Earns Rare Pediatric Disease Designation

According to a story from apnews.com, the biopharmaceutical company FibroGen, Inc., has recently announced that its investigational treatment pamrevlumab has earned Rare Pediatric Disease designation from the US Food and…

Continue Reading Experimental Duchenne Muscular Dystrophy Treatment Earns Rare Pediatric Disease Designation